914P - Comorbidities and adverse events in advanced and recurrent ovarian cancer patients in France

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Ovarian Cancer
Complications of Treatment
Cancer in Special Situations
Presenter Olivia Le Saux
Citation Annals of Oncology (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338
Authors O. Le Saux1, A. Taylor2, V. Chia3, D. Pillas2, G. Kafatos2, G. Freyer4
  • 1Department Of Medical Oncology, Centre Hospitalier Lyon-Sud, 69495 - Lyon/FR
  • 2Centre For Observational Research, Amgen Ltd, Uxbridge/GB
  • 3Center For Observational Research, Amgen Inc, Thousand Oaks/US
  • 4Department Of Medical Oncology, Centre Hospitalier Lyon-Sud, Lyon/FR



Few observational studies have reported adverse events and comorbidities in European ovarian cancer patients. We conducted a retrospective study to address these areas.


A retrospective cohort study of advanced (stage IIIB-IV) or recurrent ovarian cancer (OC) patients treated by hospital or cancer centre-based physicians (n = 23) was conducted in France. 127 patients diagnosed with OC between 2009 and 2012 and with a minimum follow-up of 6 months were included. Retrospective information on comorbidities, treatment-related adverse events (AEs) (captured over a maximum 1 year period), and deaths was abstracted into case report forms.


Of the 127 patients, 92 (72.4%) had advanced OC and 35 (27.6%) had recurrent OC; the median age was 62 years. 86.6% of patients had surgery performed during the most recent admission. 35 (27.6%) patients recurred after initial presentation, of which 16 were highly platinum sensitive (recurrence more than 12 months after stopping platinum based therapy), 11 were platinum partially-sensitive (recurrence 6-12 months of stopping platinum based therapy), 7 were platinum resistant (recurrence within 6 months of stopping platinum-based therapy or progression while receiving 2nd or later line platinum based therapy), and 1 was platinum refractory (recurrence within 6 months of the start date of 1st-line platinum-based therapy). A total of 73 comorbidities were reported in 44 patients (34.6% of patients). Vascular (10.2%), metabolism (7.1%), respiratory (5.5%), and psychiatric disorders (5.5%) were the most common. Incidence of AEs was 77.2%, of which 12.6% were classified as serious. The most common AEs were anaemia (16.5%), hematologic events (12.6%), taste change (11.8%), and headache (7.1%). Throughout the follow-up period, 12 patient deaths were reported (6 due to disease progression).


In a European hospital-based study of advanced or recurrent ovarian cancer patients, one in three patients were reported to have a comorbidity, and four in five reported a mild adverse event. The incidence rates reported in this study are comparable to those reported in previous European-based studies.


A. Taylor, V. Chia and G. Kafatos: is employed by Amgen Ltd and owns Amgen stock;

D. Pillas: is employed by Amgen Ltd; G. Freyer: is a consultant for Amgen France. All other authors have declared no conflicts of interest.